

## ***CURRICULUM VITAE***

**DATE** October 2017

**NAME** Guido Franzoso

### **PERSONAL INFORMATION**




### **NATIONALITIES**



### **ADDRESSES AND TELEPHONE NUMBERS**

**Office:** Imperial College London  
Commonwealth Research Building, Room 10N8  
Du Cane Road  
London W12 0NN  
United Kingdom  
Tel: +44 (0)20 8383 8421 (office)  
+44 (0)20 8383 8430 (laboratory)  
Fax: +44 (0)20 8383 2788 (fax)  
Email: [g.franzoso@imperial.ac.uk](mailto:g.franzoso@imperial.ac.uk)

**Home:**



### **EDUCATION**

- 09/1976-07/1981 High School (07/1981)  
Liceo Scientifico "Collegio Vescovile Barbarigo", Padua, Italy.
- 11/1981-11/1987 M.D. (11/1987)  
*Summa Cum Laude Honors*  
University of Padua Medical School, Padua, Italy.
- 11/1989-11/1993 Ph.D., Microbiological Sciences (11/1993)

Institute of Microbiology, University of Padua, Padua, Italy.  
**PROFESSIONAL APPOINTMENTS****Current:**

08/2012 to date      **Professor and Chair of Signal Transduction and Inflammation  
Head, Centre for Cell Signalling and Inflammation (CCSI)**  
Division of Immunology and Inflammation  
Department of Medicine  
Member of the British Heart Foundation Centre of Research Excellence  
Member of the Cancer Research UK Centre Steering Committee  
Faculty of Medicine  
Imperial College London, London, UK

08/2011 to date      **Honorary Consultant**  
Clinical Programme Group 1 (CPG1) 1, Medicine  
Imperial College Healthcare NHS Trust, London, UK

**Previous:**

07/2007-07/2012      **Professor and Chair  
Head, Section of Inflammation and Signal Transduction**  
Division of Immunology and Inflammation  
Department of Medicine  
Member of The British Heart Foundation Centre of Research Excellence  
Faculty of Medicine  
Imperial College London, London, UK

07/2004-06/2007      **Associate Professor (with Tenure)**  
Member of The Ben May Department for Cancer Research  
Member of The Committee on Immunology and The Committee on Cancer Biology  
The University of Chicago, Chicago, IL

12/1997-06/2004      **Assistant Professor**  
Member of The Ben May Institute for Cancer Research  
Member of The Gwen Knapp Center for Lupus and Immunology Research  
Member of The Committee on Immunology and The Committee on Cancer Biology  
The University of Chicago, Chicago, IL

11/1994-11/1997      **Visiting Associate**  
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S.A.

11/1992-11/1994      **Staff Physician** (Permanent Clinical Position; *on leave of absence*)  
Servizio di Microbiologia, Complesso Convenzionato Universita`-U.L.S.S. 21, Padua, Italy.

- 08/1991-11/1994     **Visiting Fellow**  
 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.
- 09/1990-07/1991     **Visiting Fellow**  
 Laboratory of Mycoplasma, Center for Biological Evaluation and Research, Food and Drug Administration, USA.
- 10/1988-01/1990     **First Lieutenant** (Clinical Position, Internist)  
 Division of Internal Medicine, Military Polyclinic of Padua, Italy.
- 01/1988-08/1990     **Research Fellow**  
 Institute of Microbiology, University of Padua, Italy.

## LICENSES AND REGISTRATIONS

Full Registration (No. 6154281), General Medical Council, UK

Italian Medical Doctor License

## INVITED SEMINARS AND PRESENTATIONS

- |           |      |   |
|-----------|------|---|
| June      | 1992 | Institute of Microbiology, University of Padua, Padua, Italy                                    |
| August    | 1992 | Annual Meeting of the Laboratory of Tumor Cell Biology, N.I.H., Bethesda, MD                    |
| June      | 1993 | Institute of Microbiology, University of Brescia, Brescia, Italy                                |
| June      | 1993 | Institute of Microbiology, University of Parma, Parma, Italy                                    |
| June      | 1993 | Institute of Microbiology, University of Verona, Verona, Italy                                  |
| August    | 1993 | Annual Meeting of the Laboratory of Tumor Cell Biology, N.I.H., Bethesda, MD                    |
| June      | 1994 | Institute of Microbiology, University of Padua, Padua, Italy                                    |
| June      | 1994 | Annual Meeting on Oncogenes, Frederick, MD  |
| September | 1994 | San Raffaele Institute, Milan, Italy  |
| November  | 1995 | Metabolism Branch, National Cancer Institute, N.I.H., Bethesda, MD                              |
| December  | 1995 | The National Institute on Aging, N.I.H., Baltimore, MD  |
| February  | 1996 | IKF, University of Münster, Münster, Germany  |
| February  | 1996 | Department of Pharmacology, The University of Rochester, Rochester, NY                          |
| April     | 1996 | The Imperial Cancer Research Fund, London, UK   |
| April     | 1996 | Massachusetts General Hospital, Harvard Medical School, Boston, MA                              |
| April     | 1996 | The Baylor Institute of Immunology, Dallas, TX  |
| October   | 1996 | European Oncologic Institute, Milan, Italy  |
| October   | 1996 | Ludwig Institute, Lausanne, Switzerland   |
| October   | 1996 | San Raffaele Institute, Milan, Italy  |
| March     | 1997 | The Gwen Knapp Center for Lupus and Immunology Research, The University of Chicago, Chicago, IL |

March	1997	Center for Biological Evaluation and Research, F.D.A., Bethesda, MD
May	1997	Laboratory of Immunopathology, N.I.H., Bethesda, MD
September	1997	26º Congresso Nazionale della Societa' Italiana di Micobiologia, Baveno, Italy
September	1998	Department of Rheumatology, The University of Chicago, Chicago, IL
December	1998	Walter Oncology Center, Indiana University, Indianapolis, IN
March	1999	Centro Ricerche "IRIS"/Chiron Vaccines and the University of Siena, Siena, Italy
April	1999	The Kennedy Center, The University of Chicago, Chicago, IL
January	2000	Department of Internal Medicine, The University of Padua, Padua, Italy
May	2000	Department of Medicine-Rheumatology, University of Illinois, Chicago, IL
December	2000	Department of Pathology, New York University, New York, NY
March	2001	Department of Gastroenterology, University of Padua, Padua, Italy
April	2001	Department of Pathology, University "Federico II", Naples, Italy
April	2001	AVIS Organization, Venice, Italy
June	2001	The Albert Einstein College of Medicine, New York, NY
May	2002	Department of Pathology, New York University, New York, NY
May	2002	Department of Biochemistry, University of Lausanne, Lausanne, Switzerland
June	2002	Department of Pathology, University "Federico II", Naples, Italy
June	2002	Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
September	2002	Department of Medicine, University of Pennsylvania, Philadelphia, PA
March	2003	Department of Pathology, University of Massachusetts, Worcester, MA
August	2003	19 <sup>th</sup> International Union of Biochemistry and Molecular Biology, Toronto, Canada
January	2004	Keystone Symposium, "NF-κB: Biology and Pathology", Snowbird, UT
April	2004	Department of Pathology, University of Massachusetts, Worcester, MA
April	2004	Department of Oncology, Georgetown University Medical Center, Washington, DC
November	2004	Department of Oncology, Loyola University Medical School, Chicago, IL
February	2005	Department of Pathology, New York University, New York, NY
February	2005	Department of Biology, Columbia University, New York, NY
April	2005	Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
April	2005	FIRC Institute for Molecular Oncology (IFOM) & European Institute of Oncology (IEO), Milan, Italy
October	2005	13 <sup>th</sup> Euroconference on Apoptosis, Budapest, Hungary
April	2006	Division of Investigative Sciences, Imperial College of Medicine, London, UK
May	2006	Laboratory of Immunology, N.I.H., Bethesda, MD
February	2008	Department of Academic Medicine, St Mary's Hospital, Imperial College London, London, UK
February	2008	Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee, UK
June	2008	Eric Bywaters Centre for Vascular Inflammation, Imperial College London, London, UK
October	2008	EMBO Workshop, "The NF-κB network in Development and Disease," Capri (NA), Italy

April	2009	Institute of Cancer, Barts and The London School of Medicine and Dentistry, London, UK
June	2009	UK & Ireland NF-κB Meeting, Kennedy Institute of Rheumatology, London, UK
November	2009	The National Institute for Medical Research at Mill Hill, Medical Research Council, London, UK
June	2010	12 <sup>th</sup> Naples Workshop, University of Naples "Federico II", Naples, Italy
November	2010	Universita' Popolare di Caverzere, Cavarzere, Italy
March	2011	One-day Symposium, "Academic Drug Discovery: Challenges and Perspectives", Imperial College London, London, UK
June	2011	Institute of Reproductive and Developmental Biology (IRDB), Department of Surgery and Cancer, Imperial College London, London, UK
November	2011	Humanitas Clinical Institute, Rozzano (MI), Italy
December	2011	Cell & Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
March	2012	Institute of Molecular and Cell Biology (ICMB), A*STAR, Singapore
March	2012	Mechanobiology Institute (MBI), National University of Singapore (NUS) & National Research Foundation (NRF), Singapore
March	2012	A*STAR Graduate Academy (AGA), Singapore
June	2012	International Conference on "Emerging Concepts in Cancer," Molecular Cancer Research Center (MKFZ), Charité, Universitätsmedizin Berlin, Berlin, Germany
April	2013	UK & Ireland IKK/NF-κB Meeting, University of Liverpool, Liverpool, UK
September	2013	55 <sup>th</sup> Annual Meeting of the Italian Society of Cancerology (SIC), University of Catanzaro, Catanzaro, Italy
September	2013	Liceo Amaldi, Rome, Italy
November	2013	Immunology Short Course for Clinicians and Scientists, Guest Lecture, Imperial College London and Imperial College Healthcare NHS Trust, London, UK
February	2014	Northern Institute for Cancer Institute (NICR), Newcastle University, Newcastle, UK
June	2014	Department of Immunological Oncology, National Cancer Institute "G. Pascale", Naples, Italy
March	2015	Department of Haematology, University of Leicester, Leicester, UK
April	2015	Innovations Mixers: "Lymphocyte, Virus and Cancer", Medical Research Council (MRC), Clinical Sciences Centre, London, UK
May	2015	Department of Haematology, King's College Hospital NHS Foundation Trust, London, UK
June	2015	UK & Ireland NF-κB/IKK Workshop, Sir Charles Wilson Building, Glasgow, UK
October	2015	Toxicology Unit, Medical Research Council (MRC), Leicester, UK
December	2015	57 <sup>th</sup> Annual Meeting of the American Society of Hematology (ASH), Orlando, FL
February	2016	IFOM-inStem Conference on "Inflammation and Tissue Homeostasis," Institute for Stem Cell Biology and Regenerative Medicine, National Centre for Biological Sciences (NCBS), Bangalore, India
June	2016	15 <sup>th</sup> Naples Workshop on "Bioactive Peptides," Naples, Italy ( <i>Keynote Speaker</i> )

- October 2017 BioJapan 2017 Speaker in Immuno-Oncology, Yokohama, Japan (Part of MedCity UK Delegation)  
October 2017 Tokyo Technology Institute, Yokohama, Japan

**EDITORIAL ACTIVITIES**

Ad Hoc Reviewer: *Nature Cell Biology*  
*Molecular and Cellular Biology*  
*Molecular Biology of The Cell*  
*The Journal of Immunology*  
*Cancer Research*  
*The EMBO Journal*  
*The Journal of Biological Chemistry*  
*Cell Death and Differentiation*  
*European Journal of Biochemistry*  
*Journal of Clinical Investigation*  
*Proceedings of the National Academy of Sciences (U.S.A.)*  
*Oncogene*  
*Blood*

Guest Editor: *Proceedings of the National Academy of Sciences (U.S.A.)*

**PROFESSIONAL & ADMINISTRATIVE ACTIVITIES**

- 1996 Member of the NIH Committee for the *Fellows Award for Research Excellence 1996* (FARE96)
- 2000 Member of the Faculty Search Committee, The Ben May Institute for Cancer Research, The University of Chicago
- 2000 Member of the *Ad Hoc* Committee to review the Committee on Cell Physiology
- 2000 Member of the Senior Advisory Board for the Animal Resource Center, The University of Chicago
- 2000-2005 *Ad Hoc* Reviewer, *Muster Grants*, Italian Ministry of University and Scientific Research
- 2001-2006 Co-organizer of the Cancer Biology Seminar Series, Committee on Cancer Biology, University of Chicago
- 2004 *Ad Hoc* Reviewer, *Grants* from the "Associazione Italiana per la Ricerca sul Cancro" (AIRC)

- 2004      *Ad Hoc Reviewer, Research Grant Applications* (R01) from the N.I.H., member of the ZRG1 SSS-4 Special Emphasis Panel (SEP), Immunology: Physiologic Cell Death
- 2005      *Ad Hoc Reviewer, Research Grant Applications* (R01) from the N.I.H., Cellular and Molecular Immunology-A (CMI-A) Study Section, Immunological Sciences IRG
- 2007      *Ad Hoc Member of the Academic Appointments Committee (Non-Clinical Lecturer)*, Department of Immunology, Division of Investigative Science, Imperial College London
- 2008      *Ad Hoc Reviewer, Project Grant Applications* from the Association for International Cancer Research (AICR)
- 2008      *Ad Hoc Member of the Academic Appointments Committee (Non-Clinical Lecturer)*, Department of Immunology, Division of Medicine, Imperial College London
- 2009-2013    *Ad Hoc Reviewer, Research Grant Applications* from the Medical Research Council (MRC)
- 2007-2013    *Ad Hoc Reviewer, Programme & Project Grant Applications* from Cancer Research UK
- 2010-2013    *Ad Hoc Reviewer, Research Grant Applications* from the Key Kendall Leukaemia Fund
- 2011        Member of the Advisory Panel for the Imperial College Lectureships, Department of Medicine, Imperial College London
- 2013        Member of Visiting Committee for the Agence d'Evaluation de la Recherche et des établissements d'Enseignement Supérieur (AERES), France
- 2013-2014    Chair of the Faculty Search Committee for the recruitment in the Centre for Cell Signalling and Inflammation (CCSI), Imperial College London
- 2013        Chair of the Probation Hearing Committee, Division of Immunology and Inflammation, Department of Medicine, Imperial College London
- 2013-2014    Member of the Cancer Research UK Centre Steering Committee, Imperial College London

**FUNDING & AWARDS****Past**

07/1998-06/1999    Louis Block Fund for Basic Research and Advanced Study

	"Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$22,000	Effort: 5%
	Role: PI	
01/1999-12/1999	Cancer Research Foundation Young Investigator Award Cancer Research Foundation "Regulation of apoptosis by NF-κB/Rel transcription factors"	
	Direct Costs: \$50,000	Effort: 10%
	Role: PI	
01/2000-12/2002	Damon Runyon Scholar Award Damon Runyon Cancer Research Foundation "Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$300,000	Effort: 10%
	Role: PI	
12/1999-11/2004	National Institutes of Health, 1 R01 CA084040 "NF-κB regulation of lymphocyte functions and apoptosis"	
	Direct Costs: \$989,637	Effort: 40%
	Role: PI	
05/2002	Salary Recovery Incentive Award "Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$12,247	Effort: N/A
	Role: PI	
02/2003	Salary Recovery Incentive Award "Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$13,000	Effort: N/A
	Role: PI	
11/2002-11/2003	Faculty Research Fund Award "Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$40,000	Effort: N/A
	Role: PI	
07/2002-06/2006	Cancer Research Institute Investigator Award Cancer Research Institute "The control of apoptosis by NF-κB"	
	Direct Costs: \$200,000	Effort: 5%
	Role: PI	
05/2004	Salary Recovery Incentive Award	

	"Identification of novel anti-apoptotic genes that are physiologic targets of NF-κB"	
	Direct Costs: \$6,509	Effort: N/A
	Role: PI	
06/2003-05/2010	National Institutes of Health, 5 R01 CA098583 "Roles of Gadd45β in JNK signaling, apoptosis, and cancer"	
	Direct Costs: \$1,001,250	Effort: 30%
	Role: PI	
03/2010-09/2010	M.Sc. Student, Immunology, Project Funds "Roles of NF-κB in multiple myeloma"	
	Direct Costs: £2,200	Effort: N/A
	Role: PI	
01/2005-12/2011	National Institutes of Health, 2 R01 CA084040 – Continuation "The NF-κB target, Gadd45β, in lymphocytes and liver"	
	Direct Costs: \$1,062,500	Effort: 30%
	Role: PI	
01/2008-12/2012	Cancer Research UK, Programme Grant C26587/A8839 "NF-κB target genes in inflammation-driven carcinogenesis"	
	Direct Costs: £1,262,500	Effort: N/A
	Role: PI	
01/2010-12/2012	The Kay Kendall Leukemia Fund, Project Grant KKL443 "Mechanisms for NF-κB-mediated survival in multiple myeloma"	
	Direct Costs: £202,452	Effort: N/A
	Role: Co-PI	
04/2010-12/2013	Imperial Innovations, Proof of Concept Grant, Case No. 4780 "Validation of Gadd45β-targeting therapy in multiple myeloma and other cancers"	
	Direct Costs: £15,043	Effort: N/A
	Role: PI	
09/2010-07/2013	Medical Research Council, Developmental Pathway Funding Scheme Grant G0901436; ID 95195 "Development of Gadd45β-targeting agents for multiple myeloma therapy"	
	Total Costs: £632,184	Effort: N/A
	Role: PI	
03/2012-07/2013	Medical Research Council, Developmental Pathway Funding Scheme Grant G0901436; ID 95195 – Supplement "Development of Gadd45β-targeting agents for multiple myeloma Therapy"	
	Total Costs: £176,030	Effort: N/A

	Role: PI	
01/2012-12/2013	A*STAR-Imperial Partnership (AIP) Ph.D. Programme Project Funds “Novel functions of NF-κB in cancer” Direct Costs: £26,900	Effort: N/A
02/2014-05/2014	B.Sc. Student, Immunity and Infection, Project Funds “Role of Gadd45β in macrophage differentiation and function” Direct Costs: £800	Effort: N/A
03/2014-06/2014	Kesios Therapeutics Limited “Development of new therapeutics for multiple myeloma and other malignancies” Total Costs: £58,464	Effort: N/A
10/2011-09/2014	British Heart Foundation Ph.D. Studentship FS/11/64/28945 “Molecular mechanisms of endothelial cytoprotection by CD31-mediated signals” Total Costs: £105,951	Effort: N/A
04/2016-09/2016	Role: Co-PI	
01/2013-12/2017	M.Sc. Student, Immunology, Project Funds “Roles of Gadd45β in macrophage polarisation” Direct Costs: £2,200	Effort: N/A
11/2013-05/2019	Role: PI	
04/2015-02/2017	Cancer Research UK, Programme Grant A15115 – Renewal “Roles of NF-κB in the control of inflammation and metabolism in cancer” Direct Costs: £1,834,728	Effort: N/A
11/2013-05/2019	Scheme: Grant MR/L005069/1; ID MR/K016164/1 “Treating multiple myeloma by targeting the NF-κB pathway with Gadd45β/MKK7 inhibitors” Total Costs: £5,699,027 (inclusive of NHS costs)	Effort: N/A
04/2015-02/2017	Role: PI	
04/2015-02/2017	Medical Research Council, Developmental Clinical Studies/Biomedical Catalyst Scheme: Grant MR/L005069/1; ID MR/K016164/1 – Supplement “Treating multiple myeloma by targeting the NF-κB pathway with Gadd45β/MKK7 inhibitors”	

	Total Costs: £80,863 Role: PI	Effort: N/A
04/2015-03/2018	Leukaemia & Lymphoma Research, Project Grant 847 “Developing novel therapeutics to cancer-selectively target the NF-κB pathway in Diffuse Large B-Cell Lymphoma” Direct Costs: £274,135 Role: PI	Effort: N/A
07/2016-09/2016	Kesios Therapeutics Limited “Cellular assays development” Total Costs: £22,000 Role: PI	Effort: N/A

## INVENTIONS, PATENTS AND SPIN-OUTS

### Patents

07/2003	Inventors: <b>G. Franzoso</b> , E. DeSmaele, F. Zazzeroni, S. Papa. "Methods and Compositions for Modulating Apoptosis" US Application Number: 10/626,905 Application Filing Date: July 25 <sup>th</sup> , 2003 Publication Number: US 2004/0121463 Applicant: UChicagoTech
11/2004	Inventors: <b>G. Franzoso</b> , S. Papa, C. Bubici, F. Zazzeroni. "Identification of Novel Factors that Block Programmed Cell Death or Apoptosis by Targeting JNK" US Application Number: 11/000,365 Application Filing Date: November 29 <sup>th</sup> , 2004 Publication Number: US 2005/0267022 Outcome: Granted as US 7,326,418, February 5 <sup>th</sup> , 2008 Applicant: UChicagoTech
01/2005	Inventors: <b>G. Franzoso</b> , S. Papa, C. Bubici, F. Zazzeroni. "Identification of Novel Factors that Block Programmed Cell Death or Apoptosis by Targeting JNK" US Application Number: 11/032,794 Application Filing Date: January 10 <sup>th</sup> , 2005 Publication Number: US 2005/0265970 Outcome: Granted as US 7,354,898, April 8 <sup>th</sup> , 2008 Applicant: UChicagoTech
02/2008	Inventors: <b>G. Franzoso</b> , S. Papa, C. Bubici, F. Zazzeroni. "Identification of Novel Factors that Block Programmed Cell Death or Apoptosis by Targeting JNK" US Application Number: 12/030,558

Application Filing Date: February 13<sup>th</sup>, 2008  
 Publication Number: US 2008/0247956  
 Applicant: UChicagoTech

- 10/2009 Inventors: **G. Franzoso**, L. Tornatore, M. Ruvo, S. Monti, C. Tralau-Stewart, C. Low, A. Jaxa-Chamiec.  
 “Gadd45β Targeting Agents”  
 UK Priority Application Number: 0918579.4  
 Priority Filing Date: October 22<sup>nd</sup>, 2009  
 International Application: PCT/GB2010/001970  
 Publication Number: WO 2011/048390  
 Publication Date: April 28<sup>th</sup>, 2011  
 Applicant: Imperial Innovations Limited
- 04/2011 Inventors: **G. Franzoso**, L. Tornatore, M. Ruvo, A. Palumbo, A. Rocci.  
 “Method of Diagnosis and Prognosis”  
 UK Priority Application Number: 1107118.0  
 Priority Filing Date: April 27<sup>th</sup>, 2011  
 International Application: PCT/GB2012/050947  
 Publication Number: WO 2012/146940  
 Publication Date: November 1<sup>st</sup>, 2012  
 Applicant: Imperial Innovations Limited
- 08/2014 Inventors: **G. Franzoso**, L. Tornatore, F. Begalli.  
 “Novel Therapy”  
 UK Priority Application Number: GB1414542.9  
 Priority Filing Date: August 15<sup>th</sup>, 2014  
 Applicant: Imperial Innovations Limited

## EDUCATIONAL ACTIVITIES

### Formal Teaching Responsibilities

#### *The University of Chicago:*

1999	Immunobiology	Bio.Sci. 230	2 hours
1999	Organism Biology	Bio.Sci. 119	2 hours
1999	Topics in Immunology	Bio.Sci. 352	1 hour
2000-2001	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours
2001-2002	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours
2002	Lymphocyte Activation	Immunol. 355	4 hours
2002	Graduate Course	Exp. Medicine	2 hours
	University of Naples Federio II, Italy		
2002-2003	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours
2003-2004	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours
2004-2005	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours
2005-2006	Introduction to Experimental Cancer Biology	Can.Bio. 390	35 hours

*Imperial College London:*

2013      Immunology Short Course for Clinicians and Scientists, Guest Lecture      1 hour

**Other Educational Activities**

- 1998-present   Weekly laboratory meeting  
 1999      Co-organiser, Annual Retreat of the Committee on Immunology,  
               The University of Chicago  
 2000      Co-organizer, Annual Retreat of the Committee on Immunology,  
               The University of Chicago  
 2000-2003   Monthly joint laboratory meeting with Drs. M. Peter and A. Ma groups  
 2003-2005   Monthly joint laboratory meeting with Dr. M. Peter group  
 1997-present   Participation in the Annual retreat of the Committee on Immunology  
               \* 2001 – *Award for Best Oral Presentation, E. De Smaele (Visiting Student)*  
               \* 2003 – *Award for Best Oral Presentation, S. Papa (Visiting Student)*  
 1998-2000   Committee on Immunology, Preliminary Examination Committee  
 1998-present   Committee on Cancer Biology, Preliminary Examination Committee  
 2004      Participation in the Keystone Symposium, "NF-κB: Biology and Pathology",  
               Snowbird, UT  
               \* 2004 – *Award for Best Poster Presentation, C.G. Pham (Graduate Student)*

**TRAINEES****Undergraduate and Summer Students**

- |      |                         |
|------|-------------------------|
| 1998 | Melissa Viray (B.Sc)    |
| 1999 | David S. Murray (B.Sc)  |
| 2000 | Kellean Alvarez (B.Sc)  |
| 2000 | Carrie Cox (B.Sc)       |
| 2003 | David Page (B.Sc)       |
| 2012 | Giulia Burastero (B.Sc) |
| 2013 | Kieran Sharma (B.Sc.)   |
| 2014 | Kunal Agarwal (B.Sc)    |
| 2014 | Hiu Yan Lam (B.Sc.)     |
- Indian Institute of Technology  
Imperial College London

**Rotating Graduate Students**

- |      |              |  |
|------|--------------|--|
| 1998 | Li Weng      | Committee on Cancer Biology, University of Chicago |
| 1998 | Candace Cham | Committee on Cancer Biology, University of Chicago |
| 2000 | Can Gia Pham | Committee on Pathology, University of Chicago      |
| 2004 | James Knabb  | Committee on Cancer Biology, University of Chicago |
| 2006 | Adam Cloe    | Committee on Immunology, University of Chicago     |

**Visiting Graduate Students**

- |           |                  |   |
|-----------|------------------|---|
| 1998-1999 | Filippo Navaglia | The University of Padua, Italy              |
| 1998-2001 | Enrico DeSmaele  | The University of Rome "La Sapienza", Italy |

## *Curriculum Vitae*

-14-

*Guido Franzoso, M.D., Ph.D.*

2000-2002	Salvatore Papa	The University of L'Aquila, Italy
2002-2003	Tiziana Melis	The University of Milan, Italy
2003	Giuseppe Astarita	The University of Genova, Italy
2005	Claudio Mauro	The University of Naples "Federico II"
2008-2009	Laura Tornatore	The University of Naples and the "Consiglio Nazionale delle Ricerche" (CNR), Naples, Italy
2011-2012	Valeria Severino	University of Naples, Caserta, Italy
2012	Lorenzo Carraro	Istituto Clinico Humanitas and The University of Milan, Italy
2013	Jérémie Postat	École Normale Supérieure de Cachan and Université Paris-Sud, France
2013	Valeria Severino	University of Naples, Caserta, Italy
2014	Vincenzo Pacifico	University of Parma, Italy
2015	Aurelie Dobric	University of Marseille, France
2015	Luigi D'Antonio	University of Chieti, Italy
2016-2017	Luca Savino	University of Chieti, Italy

## **Graduate Students**

2000-2005	Can Gia Pham (Ph.D.)	Committee on Pathology, University of Chicago
2004-2007	James Knabb (Ph.D.)	Committee on Cancer Biology, University of Chicago
2008-2012	Shi Chi Leow (Ph.D.)	Imperial College London, A*Star-Imperial Partnership
2008-2015	Anil Thotakura (Ph.D.)	Imperial College London
2010	Marianela Gil Curto (M.Sc.)	Immunology, Imperial College London
2014-present	Mariam Albahra (Ph.D.)	Imperial College London
2015	Hiu Yan Lam (M.Sc.)	Immunology, Imperial College London
2015	Giovanna Morsiani (M.Sc.)	Drug Discovery & Development, Imperial College London
2015	June Hwang (M.Sc.)	Drug Discovery & Development, Imperial College London
2015	Hassan Norfarazieda (Ph.D.)	Imperial College London
2016	Joshua Evans (M.Sc.)	Immunology, Imperial College London
2017	Colin Moore (M.Sc.)	Immunology, Imperial College London
2017 to date	Zareen Sultana (Ph.D.)	British Council Newton Bhabha PhD Placement

## **Post-Doctoral Fellows**

1997-2000	Giorgio Malpeli, Ph.D.	University of Parma, Italy
1997-2001	Enrico De Smaele	University "La Sapienza", Rome, Italy
1999-2003	Francesca Zazzeroni, Ph.D.	University of L'Aquila, Italy
1999-2002	Rong Cong, Ph.D.	University of Shanghai, China
2002-2012	Salvatore Papa, Ph.D.	University of L'Aquila, Italy
2004-2006	Christian Kuntzen, M.D.	University of München, Germany
2002-2007	Concetta Bubici, Ph.D.	University of L'Aquila, Italy
2008-2009	Karine Enesa, Ph.D.	Imperial College London, United Kingdom
2006-2011	Claudio Mauro, Ph.D.	University of Naples Federico II, Italy
2009-present	Laura Tornatore, Ph.D.	The University of Naples and the "Consiglio Nazionale delle Ricerche" (CNR), Naples , Italy

## *Curriculum Vitae*

-15-

*Guido Franzoso, M.D., Ph.D.*

2009-2010	Ling Li, Ph.D.	King's College London, United Kingdom
2010-2012	Marta Moretti, Ph.D.	University "La Sapienza", Rome, Italy
2010-present	Jason Bennett, Ph.D.	University College Dublin, Ireland
2012-2013	Katia Ruggero, Ph.D.	University of Padua, Italy
2012-present	Frederica Begalli, Ph.D.	University "La Sapienza", Rome, Italy
2013-present	Daria Capece, Ph.D.	University of L'Aquila, Italy
2013-2017	James Ellis, Ph.D.	Imperial College London, United Kingdom
2014-present	Daniel D'Andrea	University "La Sapienza", Rome, Italy
2015-present	Daniela Verzella, Ph.D.	University of L'Aquila, Italy

## **Ph.D. Thesis Committees**

Sridhar Rao	Committee on Immunology
Robyn Shelton	Committee on Cancer Biology
Stephen Guest	Committee on Virology
Funda Gilman	Committee on Immunology
James Lo	Committee on Immunology
Angela Parsons	Committee on Immunology
Elizabeth Alappat	Committee on Cancer Biology, <i>Chair</i>
Susan Byrne	Committee on Immunology
Bryan C. Barnhart	Committee on Immunology, <i>Chair</i>
Atsushi Tanaka	Committee on Immunology
Robert Schickel	Committee on Cancer Biology, <i>Chair</i>
Benjamin Boyerinas	Committee on Cancer Biology
Wei Xu	Committee on Cancer Biology
Rebecca L. McCrackan	Department of Medical Biology, The University of Melbourne, Australia
Delia Lozano Porras	Committee on Immunology
Claudio Mauro	Program in Molecular Oncology and Endocrinology, University of Naples Federico II, Italy
Angela Cassese	Program in Molecular Oncology and Endocrinology, University of Naples Federico II, Italy
Chiara Romano	Program in Molecular Oncology and Endocrinology, University of Naples Federico II, Italy
Yutaka Shimizu	Department of Medicine, Imperial College London, <i>Internal Examiner</i>
Ana Carina Bon Frauches Oliveira	Crick-NIMR PhD Programme, Crick Institute, <i>Secondary Supervisor</i>

## **PUBLICATIONS**

### Peer Reviewed

1. P. Burra, **G. Franzoso**, M. Salvagnini, L. Dalri, R. Naccarato. 1988. Comportamento della malondialdeide (MDA) quale indice di perossidazione lipidica e nella diagnosi delle epatopatie. In Alcol e Benessere. Ed. A. Morettini and C. Surrenti. Publ. Monduzzi. p. 283-286.

2. **G. Franzoso**, R. Cusinato, E.A. Tonin, G.A. Meloni. 1991. Attivita` della claritromicina nei confronti di micoplasmi e clamidie. G. Ital. Chemioter., 38: 159-161.
3. **G. Franzoso**, D.S. Dimitrov, R. Blumenthal, M.F. Barile and S. Rottem. 1992. Fusion of *Mycoplasma fermentans*, strain *incognitus*, with T-lymphocytes. F.E.B.S. Letters, 303: 251-254.
4. **G. Franzoso**, V. Bours, S. Park, M. Tomita-Yamaguchi, K. Kelly, U. Siebenlist. 1992. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF- $\kappa$ B-mediated inhibition. Nature, 359: 339-342.
5. V. Bours, **G. Franzoso**, K. Brown, S. Park, V. Azarenko, M. Tomita-Yamaguchi, K. Kelly, U. Siebenlist. 1992. Lymphocyte activation and the family of NF- $\kappa$ B transcription factor complexes. Curr. Top. Microbiol. Immunol., 182: 411-420.
6. V. Bours, **G. Franzoso\***, V. Azarenko, S. Park, T. Kanno, K. Brown, U. Siebenlist. 1993. The oncoprotein Bcl-3 directly transactivates through  $\kappa$ B motifs via association with DNA-binding p50B homodimers. Cell, 72: 729-739.  
\* *G. Franzoso is joint first author.*
7. K. Brown, S. Park, T. Kanno, **G. Franzoso**, U. Siebenlist. 1993. Mutual regulation of the transcriptional activator NF- $\kappa$ B and its inhibitor, I $\square$ B- $\alpha$ . Proc. Natl. Acad. Sci. (U.S.A.), 90: 2532-2536.
8. **G. Franzoso**, P.-C. Hu, G.A. Meloni, M.F. Barile. 1993. The immunodominant 90 kilodalton protein is localized on the terminal tip structure of *Mycoplasma pneumoniae*. Infect. Immun., 61: 1523-1530.
9. D.S. Dimitrov, **G. Franzoso**, M. Salman, R. Blumenthal, M. Tarshis, M.F. Barile and S. Rottem. 1993. *Mycoplasma fermentans* (*incognitus* strain) cells are able to fuse with T-lymphocytes. Clin. Infect. Dis., 17: S305-S308.
10. J.H. Segars, T. Nagata, V. Bours, J.A. Medin, **G. Franzoso**, J.C.G. Blanco, P.D. Drew, K.G. Becker, J. An, T. Tang, D.A. Stephany, B. Neel, U. Siebenlist, K. Ozato. 1993. Retinoic acid induction of Major Histocompatibility Complex class I genes in NTERA-2 embryonal carcinoma cells involves induction of NF- $\kappa$ B (p50/p65) and Retinoic Acid Receptor  $\beta$ -Retinoid X Receptor  $\beta$  heterodimers. Mol. Cell. Biol., 13: 6157-6169.
11. **G. Franzoso**, V. Bours, V. Azarenko, S. Park, M. Tomita-Yamaguchi, T. Kanno, K. Brown, U. Siebenlist. 1993. The oncoprotein Bcl-3 can facilitate NF- $\kappa$ B-mediated transactivation by removing inhibiting p50 homodimers from select  $\kappa$ B sites. EMBO J., 12: 3893-3901.
12. **G. Franzoso**, P.-C. Hu, G.A. Meloni, M.F. Barile. 1994. Immunoblot analyses of chimpanzee sera after infection and after immunization and challenge with *Mycoplasma pneumoniae*. Infect. Immun., 62: 1008-1014.

13. U. Siebenlist, **G. Franzoso**, K. Brown. 1994. Structure, regulation and function of NF- $\kappa$ B. Annu. Rev. Cell Biol., 10: 405-455.
14. U. Siebenlist, K. Brown, **G. Franzoso**. 1994. NF- $\kappa$ B: a mediator of pathogen and stress responses. In Inducible Gene Expression. Ed. P. Baeuerle. Publ. Birkhauser. p. 93-141.
15. **G. Franzoso**, P. Biswas, G. Poli, L. Carlson, K. Brown, M. Tomita-Yamaguchi, A.S. Fauci, U. Siebenlist. 1994. A family of serine proteases expressed exclusively in myelomonocytic cells specifically processes the Nuclear Factor- $\kappa$ B subunit p65 *in vitro* and may impair Human Immunodeficiency Virus replication in these cells. J. Exp. Med., 180: 1445-1456.
16. T. Kanno, K. Brown, **G. Franzoso**, U. Siebenlist. 1994. Kinetic analysis of Human T-cell Leukemia Virus type I Tax-mediated activation of NF- $\kappa$ B. Mol. Cell. Biol., 14: 6443-6451.
17. T. Kanno, **G. Franzoso**, U. Siebenlist. 1994. Human T cell leukemia virus type Tax-protein-mediated activation of NF- $\kappa$ B from p100 (NF- $\kappa$ B2)-inhibited cytoplasmic reservoirs. Proc. Natl. Acad. Sci. (U.S.A.), 91: 12634-12638.
18. K. Brown, S. Gerstberger, L. Carlson, **G. Franzoso**, U. Siebenlist. 1995. Control of I $\kappa$ B- $\alpha$  proteolysis by site-specific signal-induced phosphorylation. Science, 267: 1485-1488.
19. P.D. Drew, **G. Franzoso**, K.G. Becker, V. Bours, L.C. Carlson, U. Siebenlist, K. Ozato. 1995. NF- $\kappa$ B and Interferon Regulatory Factor-1 physically interact and synergistically induce Major Histocompatibility Class I gene expression. J. Interf. Cytok. Res., 15: 1037-1045.
20. P.D. Drew, **G. Franzoso**, K.G. Becker, V. Bours, L.C. Carlson, U. Siebenlist, K. Ozato. 1995. Interferon Regulatory Factor-2 physically interacts with NF- $\kappa$ B and inhibits NF- $\kappa$ B induction of Major Histocompatibility Class I and  $\beta$ 2-microglobulin gene expression in transfected human neuronal cells. J. Neuroimmunol., 63: 157-162.
21. L. Baldi, K. Brown, **G. Franzoso**, U. Siebenlist. 1996. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I $\kappa$ B- $\alpha$ . J. Biol. Chem., 271: 376-379.
22. **G. Franzoso**, L. Carlson, K. Brown, M. Daucher, P. Bressler and U. Siebenlist. 1996. Activation of the Serum Response Factor (SRF) by p65/NF- $\kappa$ B. EMBO J., 15: 3403-3412.
23. M. R. Ruocco, X. Chen, C. Ambrosino, E. Dragonetti, W. Liu, M. Mallardo, G. De Falco, C. Palmieri, **G. Franzoso**, I. Quinto, S. Venuta, G. Scala. 1996. Regulation of HIV-1 Long Terminal Repeats by interaction of C/EBP (NF-IL6) and NF- $\kappa$ B/Rel transcription factors. J. Biol. Chem., 271: 22479-22486.
24. **G. Franzoso**, L. Carlson, T. Sharton-Kersten, E.W. Shores, S. Epstein, A. Grinberg, T. Tran, E. Shacter, A. Leonardi, M. Anver, P. Love, A. Sher, U. Siebenlist. 1997. Critical roles for the Bcl-3 oncprotein in T cell-mediated immunity, splenic microarchitecture and germinal center reactions. Immunity, 6: 479-490.

25. K. D. Brown, **G. Franzoso**, L. Baldi, L. Carlson, L. Mills, Y-C. Lin, S. Gerstberger, U. Siebenlist. 1997. The signal response of I $\kappa$ B- $\alpha$  is regulated by transferable N- and C-terminal domains. Mol. Cell. Biol., 17: 3021-3027.
26. **G. Franzoso**, L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Brown, A. Leonardi, T. Tran, B.F. Boyce, U. Siebenlist. 1997. Requirement for NF- $\kappa$ B in osteoclast and B cell development. Genes Dev., 11: 3482-3496.
27. **G. Franzoso**, L. Carlson, L. Poljak, E.W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Sharton-Kersten, M. Anver, P. Love, K. Brown, U. Siebenlist. 1998. Mice Deficient in NF- $\kappa$ B/p52 present with defects in humoral responses, germinal center reactions and splenic microarchitecture. J. Exp. Med., 187: 147-159.
28. A. Chariot, F. Princen, J. Gielen, M.P. Merville, **G. Franzoso**, K. Brown, U. Siebenlist, V. Bours. 1999. I $\kappa$ B- $\alpha$  enhances transactivation by the HOXB7 homeodomain-containing protein. J. Biol. Chem., 274: 5318-5325.
29. D.C. St.Louis, J. Woodstock, **G. Franzoso**, P.J. Blair, L.M. Carlson, M. Murillo, M.R. Wells, A.J. Williams, D.S. Smoot, S. Kaushal, J.L. Grimes, D.M. Harlan, J.P. Chute, C.H. June, U. Siebenlist, and K.P. Lee. 1999. Evidence for distinct intracellular signaling pathways in CD34 $^{+}$  progenitor to dendritic cell differentiation from a human cell line model. J. Immunol., 162: 3237-3248.
30. B.F. Boyce, L. Xing, **G. Franzoso**, U. Siebenlist. 1999. Required and nonessential functions of nuclear factor- $\kappa$ B in bone cells. Bone, 25: 137-139.
31. A. Leonardi, H. Ellinger-Ziegelbauer, **G. Franzoso**, K. Brown, and U. Siebenlist. 2000. Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2. J. Biol. Chem., 275: 271-278.
32. E. De Smaele, F. Zazzeroni, S. Papa, D. U. Nguyen, R. Jin, J. Jones, R. Cong, and **G. Franzoso**. 2001. Induction of *gadd45* $\beta$  by NF- $\kappa$ B down-regulates pro-apoptotic JNK signaling. Nature, 414: 308-313.  
\* *News and Views*: 2001. Nature, 414: 265-266.  
\* *Highlights*: 2001. Nature Rev. Mol. Cell Biol., 2: 875.  
\* *Hot Papers*: 2003. The Scientist, 17: 32.
33. C. Guiet, E. Silvestri, E. De Smaele, **G. Franzoso**, and P. Vito. 2002. c-FLIP efficiently rescues TRAF2 $^{-/-}$  cells from TNF-induced apoptosis. Cell Death Differ., 9: 138-144.
34. R. Jin, E. De Smaele, F. Zazzeroni, D. U. Nguyen, S. Papa, J. Jones, C. Cox, C. Gelinas, **G. Franzoso**. 2002. Regulation of the *gadd45* $\beta$  promoter by NF- $\kappa$ B. DNA Cell Biol., 21: 491-503.
35. **G. Franzoso**, F. Zazzeroni, S. Papa. 2003. JNK: a killer on a transcriptional leash. Cell Death Differ., 10: 13-15.

36. M.A. Medici, M.T. Sciortino, D. Perri, C. Amici, E. Avitable, M. Ciotti, E. Balestrieri, E. De Smaele, **G. Franzoso** and A. Mastino. 2003. Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis: Role of nuclear factor- $\kappa$ B. *J. Biol. Chem.*, 278: 36059-36067.
37. F. Zazzeroni, S. Papa, E. De Smaele, **G. Franzoso**. 2003. Cell survival and Gadd45-factor deficiency. *Nature*, 424: 742.
38. N. Liu, S.M. Raja, F. Zazzeroni, S.S. Metkar, R. Shah, M. Zhang, Y. Wang, D. Broemme, W.A. Russin, J.C. Lee, M.E. Peter, C.J. Froelich, **G. Franzoso** and P.G. Ashton-Rickardt. 2003. NF- $\kappa$ B protects from the lysosomal pathway of cell death. *EMBO J.*, 22: 5313-5322.
39. F. Zazzeroni, S. Papa, A. Algeciras-Schimrich, K. Alvarez, T. Melis, C. Bubici, N. Majewski, N. Hay, E. De Smaele, M. Peter, **G. Franzoso**. 2003. Gadd45 $\beta$  mediates the protective effects of CD40 co-stimulation against Fas-induced apoptosis. *Blood*, 102: 3270-3279.
40. J.C. Lo, R.K. Chin, Y. Lee, H.-S. Kang, Y. Wang, J.V. Weinstock, T. Banks, C.F. Ware, **G. Franzoso** and Y.-X. Fu. 2003. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. *J. Clin. Invest.*, 112: 1495-1504.
41. S. Papa, F. Zazzeroni, C. Bubici, S. Jayawardena, C.G. Pham, K. Alvarez, S. Matsuda, D.U. Nguyen, A. H. Nelsbach, T. Melis, E. De Smaele, W.-J. Tang, L. D'Adamio, **G. Franzoso**. 2004. Gadd45 $\beta$  mediates the NF- $\kappa$ B suppression of JNK signaling by targeting MKK7/JNKK2. *Nat. Cell Biol.*, 6: 146-153.  
\* *Updates*: 2004. *Trends Immunol.*, 25: 402-405.  
\* *Signaling Updates*: 2004. *AfCS Nature*.
42. B.C. Barnhart, P. Legembre, E. Pietras, C. Bubici, **G. Franzoso**, M.E. Peter. 2004. CD95 ligand induces motility and invasiveness of apoptosis resistant tumor cells. *EMBO J.*, 23: 3175-3185.
43. S. Papa, F. Zazzeroni, C.G. Pham, C. Bubici, **G. Franzoso**. 2004. Linking JNK signaling to NF- $\kappa$ B: a key to survival. *J. Cell Sci.*, 117: 5197-5208.
44. C.G. Pham, C. Bubici, F. Zazzeroni, S. Papa, J. Jones, K. Alvarez, S. Jayawardena, E. De Smaele, R. Cong, C. Beaumont, F.M. Torti, S.V. Torti, **G. Franzoso**. 2004. Ferritin heavy chain upregulation by NF- $\kappa$ B inhibits TNF $\alpha$ -induced apoptosis by suppressing reactive oxygen species. *Cell*, 119: 529-542.  
\* *Comment on Articles*: 2004. *Sci. Aging Knowl. Environ.*, 46: nf102.
45. C. Bubici, S. Papa, C.G. Pham, F. Zazzeroni, **G. Franzoso**. 2004. NF- $\kappa$ B and JNK: an intricate affair. *Cell Cycle*, 3: 1524-1529.
46. C.G. Pham, S. Papa, C. Bubici, F. Zazzeroni, **G. Franzoso**. 2005. Oxygen JNKies: Phosphatases overdose on ROS. *Dev. Cell*, 8: 452-454.

47. C.G. Pham, S. Papa, C. Bubici, F. Zazzeroni, **G. Franzoso**. 2005. In the crosshairs: NF- $\kappa$ B targets the JNK signaling cascade. Curr. Med. Chem. – AIAA, 4: 569-576.
48. S. Papa, C. Bubici, C.G. Pham, F. Zazzeroni, **G. Franzoso**. 2005. NF- $\kappa$ B meets ROS: an “iron-ic” encounter. Cell Death Diff., 12: 1259-1262.
49. C. Bubici, S. Papa, C.G. Pham, F. Zazzeroni, **G. Franzoso**. 2006. The NF- $\kappa$ B-mediated control of ROS and JNK signaling. Histol. Histopathol., 21: 69-80.
50. J.C. Lo, S. Basak, E.S. James, R. Quiambo, M.C. Kinsella, M.L. Alegre, F. Weih, **G. Franzoso**, A. Hoffmann, and Y.-X. Fu. 2006. Coordination between NF- $\kappa$ B family members p50 and p52 is essential for mediating LT $\beta$ R signals in the development and organization of secondary lymphoid tissues. Blood, 107: 1048-1055.
51. A. Mittal, S. Papa, **G. Franzoso**, R. Sen. 2006. NF- $\kappa$ B-dependent regulation of the timing of activation induced cell death of T lymphocytes. J. Immunol., 176: 2183-2189.
52. S. Papa, C. Bubici, F. Zazzeroni, C.G. Pham, C. Kuntzen, J.R. Knabb, K. Dean, **G. Franzoso**. 2006. The NF- $\kappa$ B-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Diff., 13: 712-729.
53. C.M. Larsen, M.G. Døssing, S. Papa, **G. Franzoso**, N. Billestrup, T. Mandrup-Poulsen. 2006. Growth arrest- and DNA-damage-inducible gene 45 $\beta$  inhibits c-jun N-terminal kinase and extracellular signal regulated kinase and decreases IL-1 $\beta$ -induced apoptosis in insulin-producing INS-1E cells. Diabetologia, 49: 980-989.
54. H. Yang, M. Bocchetta, B. Kroczyńska, A.G. Elmishad, Z. Liu, C. Bubici, B.T. Mossman, H.I. Pass, J.R. Testa, **G. Franzoso**, M. Carbone. 2006. TNF $\alpha$  inhibits asbestos induced cytotoxicity via a NF- $\kappa$ B-dependent pathway: a possible mechanism for asbestos induced oncogenesis. Proc. Natl. Acad. Sci. (U.S.A.), 103: 10397-10402.
55. C. Bubici, S. Papa, K. Dean, **G. Franzoso**. 2006. Mutual crosstalk between reactive oxygen species (ROS) and NF- $\kappa$ B: Molecular basis and biological significance. Oncogene, 25: 6731-6748.
56. C. Centeno, M. Repici, J-Y. Chatton, B.M. Riederer, C. Bonny, P. Nicod, M. Price, P.G.H. Clarke, S. Papa, **G. Franzoso**, T. Borsello. 2007. Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell Death Diff., 14: 240-253.
57. C.G. Pham, C. Bubici, F. Zazzeroni, J.R. Knabb, S. Papa, C. Kuntzen, **G. Franzoso**. 2007. Upregulation of Twist-1 by NF- $\kappa$ B blocks cytotoxicity induced by chemotherapeutic drugs. Mol. Cell. Biol., 27: 3920-3935.
58. S. Papa, S. M. Monti, R. M. Vitale, C. Bubici, S. Jayawardena, K. Alvarez, E. De Smaele, N. Dathan, C. Pedone, M. Ruvo, **G. Franzoso**. 2007. Insights into the structural basis of the Gadd45 $\beta$ -mediated inactivation of the JNK kinase, MKK7/JNKK2. J. Biol. Chem., 282: 19029-19041.

59. C. Kuntzen, F. Zazzeroni, C.G. Pham, S. Papa, C. Bubici, J.R. Knabb, **G. Franzoso**. 2007. A method for isolating prosurvival targets of NF-κB/Rel transcription factors. Methods Mol. Biol., 399: 99-124.
60. S. Papa, F. Zazzeroni, Y.-X. Fu, C. Bubici, K. Alvarez, K. Dean, P.A. Christiansen, R.A. Anders, **G. Franzoso**. 2008. Gadd45 $\beta$  promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J. Clin. Invest., 118: 1911-1923.
61. L. Tornatore, D. Marasco, N. Dathan, R.M. Vitale, E. Benedetti, S. Papa, **G. Franzoso**, M. Ruvo, S.M. Monti. 2008. Gadd45 $\beta$  forms a homodimeric complex that binds tightly to MKK7. J. Mol. Biol., 378: 97-111.
62. C. Mauro, F. Zazzeroni, S. Papa, C. Bubici, **G. Franzoso**. 2009. The NF-κB transcription factor pathway as a therapeutic target in cancer: Methods for detection of NF-κB activity. Methods Mol. Biol., 512: 169-207.
63. A.V. Tumanov, E.P. Koroleva, P.A. Christiansen, M.A. Khan, M.J. Ruddy, B. Burnette, S. Papa, **G. Franzoso**, S. Nedospasov, Y.-X. Fu, R.A. Anders. 2009. T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology, 136: 694-704.
64. B. Liu, G. Suyeoka, S. Papa, **G. Franzoso**, A.H. Neufeld. 2009. Growth arrest and DNA damage protein 45 $\beta$  (Gadd45 $\beta$ ) protects retinal ganglion cells from injuries. Neurobiol. Dis., 33: 104-110.
65. T.D. Gilmore, N.D. Perkins, **G. Franzoso**. 2009. Getting away from it all in Capri: The 2008 EMBO Workshop on NF-κB. Cell Death Diff., 16: 651-654.
66. L. Tornatore, S.M. Montil, D. Marasco, N. Dathan, R.M. Vitale, E. Benedetti, C. Pedone, S. Papa, **G. Franzoso**, M. Ruvo. 2009. Gadd45 $\beta$  dimerization does not affect MKK7 binding. Adv. Exp. Med. Biol., 611: 367-368.
67. C.I. Svensson, T. Inoue, D. Hammaker, A. Fukushima, S. Papa, **G. Franzoso**, G. Schett, M. Corr, D.L. Boyle and G.S. Firestein. 2009. Gadd45 $\beta$  deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. Arthritis Rheum., 60: 3229-3240.
68. S. Papa, C. Bubici, F. Zazzeroni, **G. Franzoso**. 2009. Mechanisms of liver disease: the crosstalk between the NF-κB and JNK pathways. Biol. Chem., 390: 965-976.
69. H. Yang, Z. Rivera, S. Jube, M. Nasu, P. Bertino, C. Goparaju, **G. Franzoso**, M.T. Lotze, T. Krausz, H.I. Pass, M.E. Bianchi, M. Carbone. 2010. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc. Natl. Acad. Sci. (U.S.A.), 107: 12611-12616.
70. L. Ma, C. Mauro, G. Cornish, J-G Chai, D. Coe, H. Fu, D. Patton, K. Okkenhaug, **G. Franzoso**, J. Dyson, S. Nourshargh, F.M. Marelli-Berg. 2010. Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proc. Natl. Acad. Sci. (U.S.A.), 107: 19461-19466.

71. C. Mauro, S.C. Leow, E. Anso, S. Rocha, A.K. Thotakura, L. Tornatore, M. Moretti, E. De Smaele, A.A. Beg, V. Tergaonkar, N.S. Chandel, **G. Franzoso**. 2011. NF- $\kappa$ B controls energy homeostasis and metabolic adaptation via SCO2-dependent upregulation of mitochondrial respiration. *Nat. Cell Biol.*, 13: 1272-1279.  
\* Research Highlights: 2011. *Nature Asia-Pacific*, August 29.  
\* Feature Article: 2011. *Oncology Times – UK Edition*, 8: 4.  
\* Feature Article: 2011. *HER2 Support Group Forums*, August 30.  
\* Feature Article: 2011. *Nursing Times.net*, August 30.  
\* Alerts: 2011. *HealthHotel*, August 28.  
\* Press Release: 2011. *Cancer Research UK*, August 28.
72. Y. Luo, D.L. Boyle, D. Hammaker, M. Edgar, **G. Franzoso**, G.S. Firestein. 2011. Suppression of collagen-induced arthritis in growth arrest and DNA damage inducible 45 $\beta$  (Gadd45 $\beta$ ) deficient mice. *Arthritis Rheum.*, 63: 2949-2955.
73. L. Tornatore, A.K. Thotakura, J. Bennett, M. Moretti, **G. Franzoso**. 2012. The nuclear factor kappa B signaling pathway: Integrating metabolism with inflammation. *Trends Cell Biol.*, 22: 557-566.
74. M. Moretti, J. Bennett, L. Tornatore, A.K. Thotakura, **G. Franzoso**. 2012. Cancer: NF- $\kappa$ B regulates energy metabolism. *Int. J. Biochem. Cell Biol.*, 44: 2238-2243.
75. A. Barbarulo, V. Iansante, A. Chaidos, K. Naresh, A. Rahemtulla, **G. Franzoso**, A. Karadimitris, D.O. Haskard, S. Papa, C. Bubici. 2013. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. *Oncogene*, 32: 4231-4242.
76. J. Bennett, M. Moretti, A.K. Thotakura, L. Tornatore, **G. Franzoso**. 2012. The regulation of the JNK cascade and programmed cell death by NF- $\kappa$ B: mechanisms and functions. in *Trends in Stem Cell Proliferation and Cancer Research*. Ed. H. Ulrich and R. Resende. Publ. Springer-Verlag. In press.
77. G.S. Ling, J. Bennett, M. Szajna, L. Fossati-Jimack, P.R. Taylor, D. Scott, **G. Franzoso**, H.T. Cook, M. Botto. 2014. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. *Nat. Commun.*, 5: 3039.
78. L. Tornatore, A. Sandomenico, D. Raimondo, C. Low, A. Rocci, C. Tralau-Stewart, D. Capece, D. D'Andrea, M. Bua, E. Boyle, M. van Duin, P. Zoppoli, A. Jaxa-Chamiec, A.K. Thotakura, J. Dyson, B.A. Walker, A. Leonardi, A. Chambery, C. Driessens, P. Sonneveld, G. Morgan, A. Palumbo, A. Tramontano, A. Rahemtulla, M. Ruvo, **G. Franzoso**. 2014. Cancer-selective targeting of the NF- $\kappa$ B survival pathway with GADD45 $\beta$ /MKK7 inhibitors. *Cancer Cell*, 26: 495-508.  
\* FEATURED ARTICLE: 2014. *Cancer Cell*, 26: 495-508.  
\* Previews: 2014. *Cancer Cell*, 26: 447-449.  
\* Research Watch: 2014. *Cancer Discovery*, 4: 1365.  
\* Press Release: 2014. *Imperial College London*, October 13.  
\* Press Release: 2014. *Medical Research Council*, October 13.  
\* Press Release: 2014. *Laboratory Talk*, October 13.

- \* Press Release: 2014. MedicalXpress, October 13.  
\* Press Association: 2014. Yahoo News UK, October 13.  
\* Margaret's Corner: 2014. Healthblogs.com, October 22.  
\* New Release: 2014. Clinical Trial Magazine, October 27.  
\* Latest News: 2014. Ramsay Health Care UK, October 30.  
\* Web Exclusives: 2014. OncologyNurseAdvisor, October 27.  
\* News: 2014. Myeloma UK, October 20.  
\* Tech News and Literature: 2014. Science & Enterprise, October 13.  
\* News: 2014. Bio-Medicine, October 13.  
\* Press Release: 2014. Imperial Innovations, October 14.  
\* NewsPoints: 2014. FirstWorld, October 14.
- In the top 5% of all articles scored by Altmetric  
- Among the highest-scoring articles from this source (#36 of 1,159)  
- High score compared to articles of the same age (97th percentile)  
- High score compared to articles of the same age and source (87th percentile)
79. C.M. Koh, E. Khattar, S.C. Leow, C.Y. Liu, J. Muller<sup>1</sup>, W.X. Ang, Y. Li, **G. Franzoso**, S. Li, E. Guccione, V. Tergaonkar. 2015. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J. Clin. Invest., 125: 2109-2122.
80. L. Tornatore, G. Acton, N. Adams, E.A. Campbell, J. Kelly, R.M. Szydlo, M. Tarbit, S. Bannoo, D. D'Andrea, D. Capece, A. Sandomenico, J. Dyson, A. Leonardi, C. Driessens, M. Ruvo, I. Anees, M. Oblak, S. Quaid, M.J. Al-Obaidi, H. Auner, R. Benjamin, R.S. Kaczmarski, M. Kaiser, A. Mehta, H.E. Oakervee, S.A. Schey, A. Wechalekar, J. Apperley, and **G. Franzoso**. 2015. Cancer-selective targeting of the NF-κB survival pathway in multiple myeloma with the GADD45β/MKK7 inhibitor, DTP3. Blood, 126: 868.
81. E. Khattar, C.M. Koh, S.C. Leow, J. Muller, W.X. Ang, G. Franzoso, S. Li, V. Tergaonkar, E. Guccione. 2016. MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions. Nat. Commun., manuscript submitted
82. D. Verzella, J. Bennett, M. Fischietti, A.K. Thotakura, C. Recordati, F. Pasqualucci, D. Capece, D. Vecchiotti, D. D'Andrea, B. Di Francesco, M. De Maglie, F. Begalli, L. Tornatore, S. Papa, T. Lawrence, S.J. Forbes, A. Sica, E. Alesse, F. Zazzeroni, and **G. Franzoso**. 2017. Breaking innate immunosuppression in cancer via GADD45β inhibition. Cancer Res., under revision.
83. L. Tornatore, D. Capece, D. Verzella, G. Acton, E.A. Campbell, J. Kelly, M. Tarbit, N. Adams, S. Bannoo, F. Begalli, J. Bennet, D. D'Andrea, A. Sandomenico, A. Leonardi, M. Ruvo, M.J. Al-Obaidi, R. Benjamin, R.S. Kaczmarski, H. Auner, J. Apperley, and **G. Franzoso**. 2017. The safety and cancer-selective pharmacology of the NF-κB/GADD45β antiapoptotic pathway inhibitor, DTP3. J. Clin. Invest., manuscript in preparation.
84. F. Begalli, J. Bennett, D. Capece, D. D'Andrea, L. Tornatore, D. Verzella, and **G. Franzoso**. 2017. Unlocking the NF-κB conundrum: Embracing complexity to achieve specificity. Biomedicines, 5: 50.

85. J. Bennet, F. Begalli, D. Capece, D. Verzella, D. D'Andrea, L. Tornatore, and **G. Franzoso**. 2017. Taming the NF-κB pathway to combat oncogenesis. Int. J. Biochem. Cell Biol., manuscript in preparation.